Atopic Dermatitis Models

Wild Mouse 750
Wild Mouse 750
Human Xenograft Models
Cell Derived Xenograft Models
Autoimmune Disease Models
Systemic Lupus Erythematosus ModelsMultiple Sclerosis ModelsRheumatoid Arthritis ModelsPsoriasis ModelsInflammatory Bowel Disease ModelsAtopic Dermatitis Models Asthma Models
Metabolic Disease Mouse Models
Obesity ModelsDiabetes ModelsNon-alcoholic Steatohepatitis (NASH) ModelsHyperlipidemia ModelsOsteoporosis ModelsHyperuricemia Models
Humanized Immune System Models
huPBMC-NCGhuHSC-NCG-XhuHSC-NCG-hIL15huHSC-NCG
Organs or Tissue Humanized Mouse Models
Wild Mouse 765
Wild Mouse 765
Rare Disease Mouse Models
Progressive Muscular Dystrophy ModelsHemophilia A Models
Neurodegenerative Disease Mouse Models
Alzheimer’s Disease (AD) ModelsParkinson’s Disease (PD) ModelsHuntington's Disease (HD) ModelsAmyotrophic Lateral Sclerosis (ALS) ModelsTransthyretin Amyloidosis (ATTR) Models
Immuno-Oncology Mouse Models
Human Xenograft ModelsHumanized Immune Checkpoint ModelsHumanized Immune System ModelsSpontaneous Tumor Models

Atopic dermatitis (AD) is a condition that causes dry, itchy and inflamed skin. It's common in young children but can occur at any age. Atopic dermatitis is long lasting (chronic) and tends to flare sometimes. 


图片2.png


1. OXA induced AD model



图片3.png


Validation data



图片4.png

Compared with G2 (the OXA modeling group), the skin thickness of mouse back (upper left) and ear (upper right) was significantly decreased after dexamethasone administration, so were the clinical score (lower left), and the serum IgE levels (lower right). The results demonstrate that OXA-induced atopic dermatitis model can be used for efficacy testing. DXMS: dexamethasone.


图片5.png


2. MC903 induced AD model



图片6.png


Validation data

图片7.png

MC903 induces atopic dermatitis-like inflammation in BALB/c mice, and the efficacy of Crisaborole (PDE4i) was confirmed


图片8.png


3. Evaluation of Tezepelumab in Balb/c-hTSLP/hTSLPR-AD Mice(Strain NO. T059652)  


图片9.png

Validation data


图片10.png


The efficacy of Tezepelumab (anti-TSLP) in the treatment of AD was confirmed on Balb/c-hTSLP/hTSLPR Mice.


图片11.png


A mixed Th2/Th1 immune response is triggered by MC903/vitamin D3 treatment.

Tezepelumab administration significantly reduces levels of inflammatory cytokines, including Th1 Th2, in AD skin sites.


4. DNFB induced AD model  

图片12.png


Validation data


图片13.png

图片14.png